Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
• To evaluate the long-term safety of GDC-0853 over an extended treatment period of up to 52 weeks • To evaluate the efficacy of GDC-0853 (analysed separately for methotrexate-inadequate response [MTX-IR] and tumour necrosis factor-inadequate response [TNF-IR] patients) at Week 52 relative to baseline in Study GA29350
Critère d'inclusion
- Rheumatoid Arthritis